How many drugs treat Postpartum depression?

Drug Landscape tracks 3 marketed treatments for Postpartum depression (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/postpartum-depression.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Postpartum depression — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postpartum depression (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postpartum depression, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zurzuvae	ZURANOLONE	Biogen	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-4/beta-3/delta	2023-01-01
Zulresso	BREXANOLONE	Sage Therap	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
ZULRESSO®	ZULRESSO®	Supernus Pharmaceuticals, Inc.	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Biogen · 1 drug in Postpartum depression
Sage Therap · 1 drug in Postpartum depression
Supernus Pharmaceuticals, Inc. · 1 drug in Postpartum depression

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postpartum depression:

Cite this brief

Drug Landscape (2026). Postpartum depression — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postpartum-depression. Accessed 2026-06-10.

Postpartum depression full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing